EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study-Reference-Cited by-同舟云学术

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study

Published:2020-07 Issue: Volume:145 Page:186-194
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Yang Guangjian,Li Jun,Xu Haiyan,Yang Yaning,Yang Lu,Xu Fei,Xia Bing,Zhu Viola W.,Nagasaka Misako^ORCID,Yang Yan,Li Yapin,Qiu Weini^ORCID,Ying Jianming,Ou Sai-Hong Ignatius,Wang Yan

Funder

Bristol Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J. Clin.,2015

2. Cancer statistics in China, 2015;Chen;CA Cancer J. Clin.,2016

3. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;Am. J. Cancer Res.,2015

4. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications;Yasuda;Lancet Oncol.,2012

5. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics;Arcila;Mol. Cancer Ther.,2013

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current clinical practice and physicians’ insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation;BMC Cancer;2024-08-23

2. Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study;BMC Cancer;2024-08-14

3. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation;Frontiers in Oncology;2024-06-11

4. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations;Frontiers in Immunology;2024-05-07

5. First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer;Med;2024-05